Controlled release of doxorubicin from polyethylene glycol functionalized melanin nanoparticles for breast cancer therapy: Part I. Production and drug release performance of the melanin nanoparticles.
Animals
Breast Neoplasms
/ drug therapy
Cell Line
Cell Line, Tumor
Cell Survival
/ drug effects
Delayed-Action Preparations
/ chemistry
Doxorubicin
/ chemistry
Drug Carriers
/ chemistry
Drug Delivery Systems
/ methods
Drug Liberation
/ drug effects
Female
Humans
Melanins
/ chemistry
Mice
Nanoparticles
/ chemistry
Polyethylene Glycols
/ chemistry
Breast cancer
Controlled release
Doxorubicin
Melanin nanoparticle
Nano-sized drug delivery
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
30 Oct 2019
30 Oct 2019
Historique:
received:
08
05
2019
revised:
26
07
2019
accepted:
11
08
2019
pubmed:
16
8
2019
medline:
12
2
2020
entrez:
16
8
2019
Statut:
ppublish
Résumé
In this study, polyethylene glycol (PEG) conjugated melanin nanoparticles (MNPs) were prepared (PEG-MNPs). A model chemotherapy drug, doxorubicin (DOX), was loaded into the PEG-MNPs with varied concentrations (0.125, 0.250, 0.500 mg/mL). TEM images showed that, DOX-PEG-MNPs are spherical-shaped and 15 ± 2.2 nm in diameter. FTIR spectroscopy analysis demonstrated that MNPs were successfully modified with PEG. The UV-Vis spectroscopy results showed that the drug loading capacity of MNPs was 0.7 mg/ml of DOX in 2 mg/ml of PEG-MNPs. The time course data showed that, the release behavior of DOX from MNPs was primarily diffusion controlled. In vitro cytotoxicity assays demonstrated that MNP and PEG-MNP did not show any toxic effect on mouse fibroblast cells while DOX-PEG-MNP was able to inhibit the proliferation of human breast cancer cells. The results confirm that the application area of MNPs in controlled and prolonged drug release could be extended to the different types of cancer therapeutics.
Identifiants
pubmed: 31415880
pii: S0378-5173(19)30658-1
doi: 10.1016/j.ijpharm.2019.118613
pii:
doi:
Substances chimiques
Delayed-Action Preparations
0
Drug Carriers
0
Melanins
0
Polyethylene Glycols
3WJQ0SDW1A
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118613Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.